KPV availability has improved over the past year. It used to be quite rare but more suppliers have added it as demand has increased. A few notes:
- Available as lyophilized powder from select US peptide suppliers (5-10 mg vials)
- Also available in oral capsule form from some supplement-adjacent companies
- Being only three amino acids, it's relatively inexpensive to synthesize — expect $30-50 per 5 mg vial
- Molecular weight: 342.43 Da — verify on CoA
- HPLC purity should be ≥ 95% for a tripeptide (lower MW peptides can be harder to purify to 99%+ but 95% is acceptable)
The oral capsule products are probably more practical for most people, given the intended GI application. Look for products that specify the KPV content per capsule and ideally provide third-party testing.
I want to add one more research angle that's relevant. Xiao et al. (2015, PMID: 26192087) showed that α-MSH peptides (including KPV) could restore intestinal barrier integrity in models of inflammatory injury. This is significant because GLP-1 RAs can increase intestinal permeability in some individuals (often called "leaky gut," though that term is debated).
If KPV can tighten intestinal tight junctions while reducing NF-κB-mediated inflammation, it addresses two potential mechanisms by which GLP-1 RAs might exacerbate GI symptoms. That's a compelling stack rationale.
Obviously we need human data — all of this is preclinical. But among the anti-inflammatory peptides, KPV has one of the more coherent mechanistic stories for GI application.
Really appreciate this thread. I'm going to bring the Dalmasso PNAS paper to my next GI appointment and see if my doc is open to discussing it. Even if he's not, the safety profile of a naturally-occurring tripeptide seems very benign. Will report back. 🙏
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsGood research-focused discussion. Reminder that IBD management should be supervised by a gastroenterologist — KPV is not a substitute for established IBD therapies. But it's encouraging to see this kind of mechanistic analysis applied to peptides that could genuinely help a subset of our community.